HUE043661T2 - A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok - Google Patents

A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok

Info

Publication number
HUE043661T2
HUE043661T2 HUE12761789A HUE12761789A HUE043661T2 HU E043661 T2 HUE043661 T2 HU E043661T2 HU E12761789 A HUE12761789 A HU E12761789A HU E12761789 A HUE12761789 A HU E12761789A HU E043661 T2 HUE043661 T2 HU E043661T2
Authority
HU
Hungary
Prior art keywords
tcdb
clostridium difficile
neutralising antibodies
tcda
major
Prior art date
Application number
HUE12761789A
Other languages
English (en)
Inventor
David Paul Humphreys
Daniel John Lightwood
Kerry Louise Tyson
David Edward Ormonde Knight
Karine Jeannine Madeleine Herve
Joanne Elizabeth Compson
Matthew Jon Timothy Page
Andrew Charles Payne
Nicola Louise Fisher
Brendon Mackenzie
Matthew Cox
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE043661(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HUE043661T2 publication Critical patent/HUE043661T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
HUE12761789A 2011-09-16 2012-09-10 A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok HUE043661T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US201261638731P 2012-04-26 2012-04-26

Publications (1)

Publication Number Publication Date
HUE043661T2 true HUE043661T2 (hu) 2019-08-28

Family

ID=46881094

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12761789A HUE043661T2 (hu) 2011-09-16 2012-09-10 A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok

Country Status (29)

Country Link
US (2) US10752676B2 (hu)
EP (2) EP2758432B1 (hu)
JP (3) JP6152107B2 (hu)
KR (1) KR20140063825A (hu)
CN (2) CN103958544B (hu)
AU (1) AU2012307157B2 (hu)
BR (1) BR112014006175B1 (hu)
CA (1) CA2848611A1 (hu)
CL (1) CL2014000491A1 (hu)
CO (1) CO6930310A2 (hu)
CY (1) CY1121673T1 (hu)
DK (1) DK2758432T3 (hu)
EA (1) EA032475B1 (hu)
EC (1) ECSP14013316A (hu)
ES (1) ES2729278T3 (hu)
HK (1) HK1199463A1 (hu)
HR (1) HRP20190917T1 (hu)
HU (1) HUE043661T2 (hu)
IL (1) IL231167A0 (hu)
LT (1) LT2758432T (hu)
MX (1) MX2014002769A (hu)
PE (1) PE20141547A1 (hu)
PL (1) PL2758432T3 (hu)
PT (1) PT2758432T (hu)
SG (2) SG10201701055WA (hu)
SI (1) SI2758432T1 (hu)
TN (1) TN2014000101A1 (hu)
WO (1) WO2013038156A1 (hu)
ZA (1) ZA201402760B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
US10226523B2 (en) * 2013-04-22 2019-03-12 The Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
US9926345B2 (en) 2014-02-18 2018-03-27 The Hospital For Sick Children Compositions and methods for treating or preventing Clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
EP3283103A4 (en) * 2015-04-15 2018-12-05 Medimmune, LLC Methods for treating clostridium difficile infection and associated disease
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP5220248B2 (ja) 1997-08-29 2013-06-26 アンチジェニックス・インコーポレイテッド アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
CA2507018C (en) * 2002-11-26 2014-03-25 John C. Alverdy Materials and methods for preventing and treating microbe-mediated epithelial disorders
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1766093T3 (pl) * 2004-02-06 2011-11-30 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
CA2592639C (en) 2004-12-27 2013-07-30 Andrew F. Kirby Reduced foam dispersions and formulations therefor
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
EP2271366A4 (en) * 2008-02-28 2012-06-20 3M Innovative Properties Co ANTIBODIES DIFFICULT CLOSTRIDIUM SPORES AND USES THEREOF
EP3722310A1 (en) * 2008-06-25 2020-10-14 Novartis AG Stable and soluble antibodies inhibiting vegf
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体
EP2558493B1 (en) * 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
JPWO2014061783A1 (ja) * 2012-10-19 2016-09-05 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
US20200377578A1 (en) 2020-12-03
JP2020037555A (ja) 2020-03-12
CN108424449A (zh) 2018-08-21
SG11201400193SA (en) 2014-05-29
EP3617227A2 (en) 2020-03-04
CN103958544B (zh) 2018-04-24
US20140348844A1 (en) 2014-11-27
US10752676B2 (en) 2020-08-25
EA201400345A1 (ru) 2014-09-30
LT2758432T (lt) 2019-06-10
JP6152107B2 (ja) 2017-06-21
EA032475B1 (ru) 2019-06-28
SG10201701055WA (en) 2017-03-30
KR20140063825A (ko) 2014-05-27
NZ623293A (en) 2016-05-27
BR112014006175A2 (pt) 2017-04-04
DK2758432T3 (da) 2019-06-03
EP2758432B1 (en) 2019-03-06
ES2729278T3 (es) 2019-10-31
ZA201402760B (en) 2016-03-30
HRP20190917T1 (hr) 2019-07-26
WO2013038156A1 (en) 2013-03-21
PT2758432T (pt) 2019-06-14
CA2848611A1 (en) 2013-03-21
SI2758432T1 (sl) 2019-07-31
AU2012307157A1 (en) 2014-04-24
CY1121673T1 (el) 2020-07-31
HK1199463A1 (en) 2015-07-03
CL2014000491A1 (es) 2014-12-26
ECSP14013316A (es) 2014-08-29
CN103958544A (zh) 2014-07-30
PL2758432T3 (pl) 2019-08-30
EP3617227A3 (en) 2020-06-03
AU2012307157B2 (en) 2017-08-03
BR112014006175B1 (pt) 2020-02-11
MX2014002769A (es) 2014-06-11
JP2015501286A (ja) 2015-01-15
JP2017149773A (ja) 2017-08-31
EP2758432A1 (en) 2014-07-30
TN2014000101A1 (en) 2015-07-01
IL231167A0 (en) 2014-04-30
PE20141547A1 (es) 2014-10-25
CO6930310A2 (es) 2014-04-28
JP6603685B2 (ja) 2019-11-06

Similar Documents

Publication Publication Date Title
HK1199463A1 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile tcda tcdb
HK1210494A1 (zh) 用於細胞培養的裝置和方法
HK1199905A1 (en) Culturing of mesenchymal stem cells
IL236672A0 (en) System and methods for preparing vegetable cells from animal fats
HK1199886A1 (en) Clostridium difficile antibodies
EP2900808A4 (en) METHOD FOR DIFFERENTIATING STEM CELLS IN CHONDROCYTES
HRP20190018T1 (hr) Postupci i sustavi za saharizaciju biomase
HK1216999A1 (zh) 針對艱難梭菌的抗體
ZA201504388B (en) Method for culturing pluripotent stem cells
EP2714923A4 (en) METHOD AND COMPOSITIONS FOR DETECTING FUNCTIONAL CLOSTRIDIUM DIFFICILE TOXINS
EP2780351A4 (en) LIPOTHEICHOIC ACID OF DIFFICULT CLOSTRIDIUM AND USES THEREOF
AP2014007559A0 (en) Neutralising antibodies to the major exotoxins TCDA and TCDB of clostridium difficile
IL231661A0 (en) Clostridium difficile antibodies
GB201103718D0 (en) Isolation of cells